PET/CT offers excellent accuracy in the staging of high-risk prostate cancer (PCa), yet outcomes-based evidence of the clinical benefit remains limited. We aimed to determine whether the rates of ...

BALTIMORE, May 12, 2026 (GLOBE NEWSWIRE) -- Today, the American Urological Association (AUA), in partnership with the Society of Urologic Oncology (SUO), released the 2026 amendment to the Advanced ...

Testosterone replacement therapy improved function without PSA recurrence in prostate cancer survivors with hypogonadism.

Using Stockholm3 testing along with PSA threshold may identify more men with biochemical recurrence after prostate cancer surgery. PSA thresholds alone do not identify all men with prostate cancer ...

CLARIFY: Positron emission tomography using 64Cu-SAR-bisPSMA in patients with high-risk prostate cancer prior to radical prostatectomy (a phase 3 diagnostic study). Vibostolimab coformulated with ...

After surgical removal of the prostate to treat prostate cancer, clinicians monitor Prostate Specific Antigen (PSA) levels. Persistently elevated PSA levels indicate residual cancer and are linked to ...

Patients who developed biochemical recurrence had a higher PSA at diagnosis, more advanced pT stages, a higher rate of pN1 stage disease, a higher rate of R1 or Rx resection, and a higher rate of ...

Non-inferior salvage treatment–free survival at 30 months favored HIFU (90%) versus salvage radical prostatectomy (86%), ...

This is an intelligent monitoring tool designed to support clinicians in keeping a close, ongoing watch over patients after ...

Most men with low-grade prostate cancer have an excellent prognosis, with a five-year survival rate of more than 99%. But ...